**Medical oncology department publications**

1. **Prof. Rasha Haggag publications:**

**قائمة بالأبحاث المدرجة على موقع Scopus ))**

1. Shereen El Shorbagy, Fouad abuTaleb, Hany A. Labib, Huda Ebian, Ola A. Harb, Mona Saeed Mohammed, Hanaa A. Rashied, Khaled A. Elbana, **Rasha Haggag**. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib versus Metformin Sorafenib Combination. J Gastrointest Canc (2020). <https://doi.org/10.1007/s12029-020-00389-w>
2. Ezzat, T., Amr, W., Mohamad, H., **Haggag, R.,** Allah, M.A.K.A. Impact of neoadjuvant chemotherapy on the surgical management of patients with locally advanced breast cancer requiring initial mastectomy. Surgical Chronicles. Volume 24, Issue 4, 2019, Pages 185-189.
3. Hussein Khaled, Fouad Abu-Taleb, **Rasha Haggag.** Hepatitis C Virus and non-Hodgkin’s lymphomas: A minireview. Journal of Advanced Research · December 2016. DOI: 10.1016/j.jare.2016.11.005.
4. [Ola A. Harb](https://www.researchgate.net/researcher/2108080831_Ola_A_Harb), [**Rasha Haggag**](https://www.researchgate.net/profile/Rasha_Haggag2), [Maged M. Ali](https://www.researchgate.net/researcher/2115430932_Maged_M_Ali), Shereen El Shorbagy, Abeer M. Abdelbary, Lobna A. Abdelaziz, Reham A. Salim, and Khaled M. Abdel Wahab. [The prognostic role of NEDD9 and P-38 protein expression levels in urinary bladder transitional cell carcinoma.](https://www.researchgate.net/publication/308165352_The_prognostic_role_of_NEDD9_and_P-38_protein_expression_levels_in_urinary_bladder_transitional_cell_carcinoma?ev=prf_pub) Journal of Oncology 2017(2017).
5. [Doaa Hasan](https://www.researchgate.net/profile/Doaa_Hasan), [Ayman F. Ahmed](https://www.researchgate.net/researcher/2114585802_Ayman_F_Ahmed), [**Rasha Haggag**](https://www.researchgate.net/profile/Rasha_Haggag2), [Abd el motaleb Mohamed](https://www.researchgate.net/researcher/2114573575_Abd_el_motaleb_Mohamed). Ultrasound elastography in pathological enlarged cervical lymph nodes compared to histopathology. Egyptian Journal of Radiology and Nuclear Medicine · August 2016.DOI: 10.1016/j.ejrnm.2016.07.008.

### Jamal Zekri, Ayman Ramadan, Muthu Kumar, Rasha H*aggag.* Abiraterone Acetate in Patients with Advanced Castrate Resistant Prostate Cancer: Initial Real Life Experience in 2 Cancer Units. Journal of Analytical Oncology. [Vol 5, No 1 (2016)](https://www.lifescienceglobal.com/pms/index.php/jao/issue/view/221).

1. [Zekri AR](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zekri%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)1, [Hassan ZK](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hassan%20ZK%5BAuthor%5D&cauthor=true&cauthor_uid=25921176), [Bahnassy AA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bahnassy%20AA%5BAuthor%5D&cauthor=true&cauthor_uid=25921176), [Khaled HM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Khaled%20HM%5BAuthor%5D&cauthor=true&cauthor_uid=25921176), [El-Rouby MN](http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Rouby%20MN%5BAuthor%5D&cauthor=true&cauthor_uid=25921176), [Haggag RM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Haggag%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=25921176), [Abu-Taleb FM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Abu-Taleb%20FM%5BAuthor%5D&cauthor=true&cauthor_uid=25921176). Differentially expressed genes in metastatic advanced egyptian bladder cancer. Asian Pac J Cancer Prev. 2015; 16(8):3543-9.‎
2. [Elsamany SA](http://www.ncbi.nlm.nih.gov/pubmed?term=Elsamany%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=25040981) , [Alzahrani AS](http://www.ncbi.nlm.nih.gov/pubmed?term=Alzahrani%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [Mohamed MM](http://www.ncbi.nlm.nih.gov/pubmed?term=Mohamed%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [Elmorsy SA](http://www.ncbi.nlm.nih.gov/pubmed?term=Elmorsy%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [Zekri JE](http://www.ncbi.nlm.nih.gov/pubmed?term=Zekri%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [Al-Shehri AS](http://www.ncbi.nlm.nih.gov/pubmed?term=Al-Shehri%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [**Haggag RM**](http://www.ncbi.nlm.nih.gov/pubmed?term=Haggag%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [Alnagar AA](http://www.ncbi.nlm.nih.gov/pubmed?term=Alnagar%20AA%5BAuthor%5D&cauthor=true&cauthor_uid=25040981), [El Taani HA](http://www.ncbi.nlm.nih.gov/pubmed?term=El%20Taani%20HA%5BAuthor%5D&cauthor=true&cauthor_uid=25040981). Clinico-pathological patterns and survival outcome of colorectal cancer in young patients: western Saudi Arabia experience. [Asian Pac J Cancer Prev.](http://www.ncbi.nlm.nih.gov/pubmed/25040981) 2014; 15(13):5239-43.
3. **Rasha Haggag**, Kamel Farag, Fouad Abu-Taleb, Sameh Shamaa, Abdel-Rahman Zekri, Tarek ELBolkainy, Hussein Khaled: Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial—an update. Medical Oncology, December 2013, 31:811. <http://dx.doi.org/10.1007/s12032-013-0811-5>.
4. Al-Zahrani AS, El-Kashif AT, **Haggag RM**, Alsirafy SA. Pattern of cancer deaths in a saudi tertiary care hospital. Am J Hosp. Palliat. Care. 2013;30(1):21-24. doi:10.1177/1049909112437574
5. El-Hariri M, Gouhar G, **Haggag R.** Whole-body FSE STIR MR imaging of lymphoma Egyptian Journal of Radiology and Nuclear Medicine (2011) 42(1) 77-85.DOI: 10.1016/j.ejrnm.2011.01.001

**قائمة بالأبحاث الدولیة غیر المدرجة على موقع Scopus ))**

1. Fouad Abu-Taleb, Rasha Haggag, Yasser Elnaggar, and Ahmed Embaby: Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients. Journal of Cancer ResearchVolume 2014 (2014), Article ID 982080. <http://dx.doi.org/10.1155/2014/982080>
2. Hany A Labiband, Rasha Haggag. CD4+CD25+highFoxP3 regulatory T-Cells in typical and atypical Philadelphia +ve CML as regard response to Imatinib therapy. *J Am Sci*2015;11(5):34-41]. (ISSN: 1545-1003).[http://www.jofamericanscience.org](http://www.jofamericanscience.org/).
3. Rasha Haggag, Jamal Zekri, Kamel Farag (2015); Assessment of initial real life experience with Abiraterone Acetate in patients with castrate resistant prostate cancer: A retrospective study in Saudi Arabian patients Int. J. of Adv. Res. 3 (6). 940-946] (ISSN 2320-5407). [www.journalijar](http://www.journalijar).
4. Hussein Khaled, Hamdy Abdel Azim, Emad Barsoum, George Chahine, Ali Shamseddine, Gamal Abdel Metaal Abbas, Omar Abdul Rahman Jazeih, Rasha Haggag, Atef Badran. A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma. MOLECULAR AND CLINICAL ONCOLOGY. 3, pages: 1099-1102, 2015. DOI: 10.3892/mco.2015.603.
5. Shereen El Shorbagy , Rasha Haggag, [Nashwa Alazizi](https://www.researchgate.net/researcher/2084236134_Nashwa_Alazizi), [Tarek Abouzeid](https://www.researchgate.net/researcher/2093208429_Tarek_Abouzeid). CD56 and CD19 Antigens Expression in Acute Myeloid Leukemia. International Journal of Science and Research (IJSR). 2016, 5(1):523 ·
6. Mona Hassanein · Rasha Haggag · Shereen M. El Shorbagy · Hoda F. Ebian. Prognostic Value of Hematogones in Patients with Acute Myeloid Leukemia in First Complete Remission. Blood Disord Transfus 2015, 6: 6.
7. Harb O, Hegazy A, Ali M, Haggag R. Prognostic Implication of MYb-Like, Swirm and Mpn Domain-Containing Protein-1 and Twist-1 in Renal Cell Carcinoma. J Interdiscipl Histopathol. Online First: 26 Feb, 2016. [doi:10.5455/jihp.20160226125558](http://dx.doi.org/10.5455/jihp.20160226125558).
8. Ola A. Harb, Abdelmonem A. Hegazy, Loay M Gertallah, Rasha Haggag, Shereen El Shorbagy. Prognostic Value of Immunohistochemical Expressions of the Stem Cell Biomarker "LGR5" and the Proliferation Biomarker "TPX2" in Colorectal Carcinoma. Journal of Tumor 2016 June; 4(3): 426-434.
9. Ola A. Harb, Amira Amin Salem, Rasha Haggag, Shereen El-Shorbagy. Immunohistochemical Expressions of, SQSTM1 / p62, Beclin-1 and SOX4 in Infiltrating Duct Carcinoma of the Breast. Egyptian Journal of Pathology, July 2016 - Volume 36 - Issue 1 - p 95–103.
10. Ola A. Harb, Lubna O. Abdel–Salam, Dina A. Khairy, Rasha Haggag. Prognostic Value of Snail-1and Beta-Catenin Immunostaining in Astrocytoma. International Journal of Advanced Research 4(4):1055-1066 · May 2016.
11. Haggag R, Hussein O, El Moaty HA, Omran A, Ebian H. Study of Plasma Endostatin Level in Patients with Acute Myeloid Leukemia. Adv Oncol Res Treat 1: 107. doi:10.4172/aot.1000107 (2016).
12. Ola A. Harb, Rasha Haggag , Amira Amin Salem, Walid Abdalla Abdesalam, Reham Amin Salim. Predictive and prognostic value of SALL4 and Tau protein in Serous Ovarian Cancer patients treated with chemotherapy. Journal of Advanced Research 4(7):602-616 · July 2016.
13. Jamal Zekri, Kamel Farag,Rawan Al-Saadi, [Rasha Haggag](https://www.researchgate.net/profile/Rasha_Haggag2). Safety and efficacy of biweekly cetuximab based chemotherapy for patients with metastatic colorectal cancer. *J Unexplored Med Data* 2016; 1:15-20.
14. Rasha Haggag, Dina A. Khairy, Abla S. Mahmoud,Ola A Harb, Reham A. Salem , Marwa N. Abdel hafez, Fady M. Habib, Loay M Gertallah. Prognostic role of H3K9 methyltransferase G9a and Sprouty 1 in colorectal carcinoma. Adv Oncol Res Treat 1:111
15. Lubna O. Abdel-Salam, Hala M. El-hanbuli, Mostafa A. Abousarie and Rasha Haggag. Clinicopathological Significance Of Cancer Stem Cells (Cd 44 And Cd133) And Inflammatory Microenvironment (Tams And Mast Cells) In Colorectal Cancer: Immunohistochemical Study. International Journal of Advanced Research 4(12) · December 2016. DOI: 10.21474/IJAR01/xxx.
16. *Shereen El-Shorbagy, Rasha Haggag , Huda F Ebian, Hany A Labib and Ola A Harb*. Prognostic Impact of 25-Hydroxyvitamin D Levels in Egyptian Patients with Breast Cancer. J Cancer Sci Ther 2017, 9:6. DOI: 10.4172/1948-5956.1000466.
17. Ahmed Aly Nagy, , Hosam Darweish, Hend M. Hamdey Rashed Elkalla, Heba Abdu-allah, Lamiaa Moustafa Ahmed, Ebtehal Mohamed Salah, MSc6, Rasha Haggag. Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study. Cancer Sci Ther 2018, 10:2 DOI: 10.4172/1948-5956.1000513.
18. Rasha Haggag, Naglaa A. Mostafa, Marwa Nabil et al., Prognostic significance of CXCR4 and mTOR expression in diffuse large B-cell lymphoma patients. Journal of Solid Tumors. Vol 9, No 1. (2019)

**قائمة بالأبحاث العلمیة المحلیة**

1. **Mona A. El-Hariri, Ghada K. Gouhar, Rasha M. Haggag (2011): Whole-body FSE STIR MR imaging of lymphoma. The Egyptian Journal of Radiology and Nuclear Medicine (2011): 42, 77–85.**
2. **Mostafa, Naglaa A., Fathi, AnanHaggag, Rasha, Ashour, Hassan Salem, Reham.** **Significance of Combined Analysis of PARP1 and EZH2 Expression as Potentially Targetable Biomarkers in Breast Cancer. Egyptian Journal of Pathology:** [**December 2018 - Volume 38 - Issue 2 - p 266–274**](https://journals.lww.com/ejpathology/pages/currenttoc.aspx)
3. **Abd Allah, M., Abdellatif, T., Amr, W., Abdel Moneim, H., Haggag, R. (2020). Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer. Zagazig University Medical Journal, 26(4), 640-648. doi: 10.21608/zumj.2019.14080.1283.**
4. **Al Shaimaa Hatem email ; Ahmed Gab~Allah; Rania Ghonaim2; rasha Haggag. Prognostic Impact of microRNAs (miR-155, miR-10a, let-7a) on the Outcome of Adult Patients with Acute Myeloid Leukemia.** DOI: [10.21608/zumj.2019.14277.1302](https://dx.doi.org/10.21608/zumj.2019.14277.1302)
5. **Manal Mohammad Easa; Nagwa Mohammad Shawky; Nashwa Mohammad Al-Azizi; Rasha Haggag. "Abnormalities Of Chromosome 17 In Patients With Myeloid Malignancies.". Zagazig University Medical Journal, 2020, doi: 10.21608/zumj.2020. 20514.1638.**
6. **Mohamed elprince, R., Ahmad, E., Abdel-motty, A., Haggag, R. (2020). FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34. Zagazig University Medical Journal, -. doi: 10.21608/zumj.2020.23639.1726**

**Conference publications**

1. F. Abu-Taleb, Ibraheem Amin, Saad Elesh, R. Haggag: Study of vascular endothelial growth factor (VEGF) and vascular cell adhesion molecule-1(VCAM-1)in metastatic breast cancer (MBC) and response to weekly docetaxel protocol.16th ICACT , Feb. 1th -4th 2005, Paris, France.
2. H. M. Khaled, F. Abu-Taleb, A. Zekri, R. Haggag (2010): Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder. ASCO annual meeting. Vol (28), No 15S, part I, page: 359s, (abstract: 5472).
3. H. Khaled, F. Abu-Taleb, R. Haggag and A. Zekri (2011): Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial. Journal of Clinical Oncology, 2011 Genitourinary Cancers Symposium. Vol (29), No 7\_suppl (March 1 Supplement), 2011: 266.
4. Rasha Mohamed Haggag, Kamel Farag, Fouad Abu-Taleb, Sameh Shamaa, Abdel-Rahman Zekri, Tarek ELBolkainy, Hussein Mustafa Khaled (2013);Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial: An update. J Clin Oncol 31, 2013 (suppl; abstr 4537), poster presentation.
5. R. Haggag and F. AbuTaleb. (2013): The outcome of acute myeloid leukemia presenting with leucopenia: A retrospective study. UAE CANCER CONGRESS 2013 (POSTER PRESENTATION).
6. Elsamany, A. Alzahrani, M. Mahroos, A. Elnagar, R. Haggag, H. El Taani: Clinico-pathological pattern of colorectal cancer in young patients,western Saudi Arabia experience. Asia-Pacific Gastroenterology Cancer Summit 2013. poster presentation.
7. Shereef Elsamany, Abdullah Saeed Alzahrani, Mervat Mahrous, Soha Elmorsy, Jamal M Zekri, Ahmed Alshehri, Rasha Mohamed Haggag, Ahmed Abdel Raheem Ahmed, Hani A. El Taani (2014); Clinicopathologic patterns and survival outcome of colorectal cancer in young patients: Western Saudi Arabia experience. J Clin Oncol 32, 2014 (suppl; abstr e14629).
8. Rasha Haggag , Jamal  Zekri, Kamel Farag : Assessment of initial real life experience with Abiraterone Acetate in patients with castrate resistant prostate cancer: A retrospective study in Saudi Arabian patients. ASUCOC 2014 (poster presentation) (Abstract#3).
9. Rasha Haggag, Ahmad Zahran, Fouad Abou-Taleb: Clinicopathological features of breast cancer molecular subtypes in Egyptian women reside at Sharkia governorate. ASUCOC 2014 (poster presentation) (Abstract#5).
10. Rasha Haggag, Ola Hussein, Hanaa Abd El Moaty, Alaa Omran, Hoda Ebian. Study of Plasma Endostatin Level In Patients With Acute Myeloid Leukemia. EHA20, e-poster display, (abstract#E925).
11. Mona Hassanein, Rasha Haggag Shereen El Shorbagy, Hoda F.Ebian. Prognostic value of Hematogones in patients with acute myeloid leukemia in first complete remission. EHA20, abstract publications, (abstract # PB1635).
12. Shereen El Shorbagy, Rasha Haggag, Hoda F.Ebian. Prognostic impact of 25-hydroxyvitamin D levels in Egyptian patients with breast cancer. The Breast 24(3):S73-S74 · November 2015
13. Samy A. Alsirafy , Dina E. Farag , Mostafa S. El-Haddad2, Rasha Haggag, Omar O. Zaki , Noha Y. Ibrahim, Ahmad M. Hammad. Do Egyptian patients know their diagnosis of cancer?. European Journal of Cancer, Vol. 51, S217, Sept. 2015.
14. Thoraya Abdel Hamid, Hossam Mahmoud, Fouad Abu- Taleb, Asmaa Mahmoud, Asmaa Salama, Rasha Haggag, Hussein Khaled. Response to two treatment regimens in adult Egyptian patients with Burkitt’s lymphoma.European Journal Of Cancer. Sept.2015,Volume 51, Supplement 3, Page S655
15. Rasha Haggag, Fouad Abu-Taleb, Hussein Khaled. Rituximab-Induced Hepatitis C Virus Reactivation in HCV-positive patients with diffuse large B-cell lymphoma. *Journal of Clinical Oncology.2016,*  34, no. 15\_suppl Published online May 11, 2017. DOI: 10.1200/JCO.2016.34.15\_suppl.e19039.
16. Ola A. Harb, Rasha Haggag, Maged M. Ali . The prognostic role of NEDD9 and P-38 protein expression levels in urinary bladder transitional cell carcinoma . Global congress on bladder cancer. Belgium. 2016.
17. Jamal Zekri, Kamel Farag, Rasha Haggag. Safety and Efficacy of Biweekly Cetuximab Based Chemotherapy for Patients with Metastatic Colorectal Cancer", reference #612 has been accepted for poster presentation at the ESMO 18th World Congress on Gastrointestinal Cancer (2016).
18. *Rasha Haggag, Shereen M. El Shorbagy, Hoda F. Ebian, Hany A Labib.*  Prognostic value of Serum Cripto-1 in patients with non-small cell lung. Pan Arab Journal of Oncology/Vol. 9/No. 2/June 2016.
19. Shereen El Shorbagy, Rasha Haggag, Fouad abutaleb, Hany A. Labib, Huda Ebian2,Ola A.Harb, Mona Saeed Mohammed , Hanaa A. Rashied, Khaled A Elbana, Sameh Saber ."Prognostic Significance of VEGF and HIF 1 α in Hepatocellular Carcinoma Patients receiving sorafenib versus metformin sorafenib combination", reference #524, accepted for poster presentation at the ESMO 19th World Congress on Gastrointestinal Cancer.
20. Fouad Abu-Taleb, Rasha Haggag, Heba Abdallah, Lobna Abdelaziz, Hanaa Rashied.Clinicopathologic features and pattern of care of renal cell carcinoma: A retrospective study from Egypt.BGO, 2015.
21. Ahmed Aly Nagya, Hossam Darwishb, Hend M. Hamdey Rashed Elkallac, Heba Abdallahd, Lamiaa Moustafa Ahmeda, Ebtehal Mohamed Salaha, Rasha Haggag .Factors Affecting Survival in Urinary Bladder Cancer Egyptian Patients: A Multicentre Retrospective Study. Poster presentation. BLADDR 2017.

1. A prospective Multicenter Study of primary breast lymphoma in Rutiximab Era: Prognostic Implication of Beta-2 microglobulin and interleukins-6. Oral poster at ASU-ICOC Egypt. November 2017.
2. Ahmad M. Hammad, Dina E. Farag, Mostafa S. El-Haddad, Rasha Haggag, Omar O. Zak2, Noha Y. Ibrahim, Samy A. Alsirafy. Awareness of Diagnosis in Patients with Cancer: A Study from Egypt. *Research in Oncology. December 2016; Vol. 12, No. 2: 60-63.DOI: 10.21608/resoncol.2016.332.1011.*
3. Ezz Elarab E, Hamada A, Mostafa A. A prospective multicenter study of primary breast lymphoma in the rituximab era: Prognostic implication of beta 2 microglobulin and interlukin-6 & interlukin-10. October 2018. Annals of Oncology 29(suppl\_8). DOI: 10.1093/annonc/mdy286.028.
4. **Prof. Fouad abuTaleb publications:**

**1- Weekly paclitaxel and carboplatin as first line treatment of metastaic breast cancer: Correlation of response with p53 status. Abstract Book, 19th ICACT, Feb. 5-8, 2008, Paris, France.**

**2- Evaluation of Response to Leuprolide Acetate in Advanced Hepatocellular Carcinoma and its Relation to Androgen Receptor Expression. Ann Oncol; Suppl 7 : 9th World Congress on Gastrointestinal Cancer 28 June-July 1, 2007: Barcelona, Spain.**

**3- Cyclin D3 as a predicitive factor in diffuse large B-cell lymphoma.**

**Abstract Book, 18th ICACT, Feb. 6th — 9th, 2007, Paris, France.**

**4- Prognostic significance of minimal residual disease in patients with acute promyelocytic leukemia. Abstract Book, 18th ICACT, Feb. 6th9th 2008, Paris, France.**

**5- Elsawy W ,Abou Taleb F ,Abdel kader M,et al**. Feasibility of Breast Conservation after Neoadjuvant Chemotherapy in 58 Patient with Locally Advanced Breast Cncer Using p53 and MDR1 Genes as Predictor of Response. Journal of the Egyptian Nat.Cancer Inst.2002;14(1):17-28.

**6- Evaluation of p53 in relapsed and refractory aggressive NHL and response to DHAP protocol. Abstract Book, 17 ICACT, 2006, Paris, France.**

**7- Study of S.VEGF and S.BGFR in patients with refractory NHL and response to ICE protocol. Annals of Oncology, 9th International Conference on Management of Lymphoma, 8-11 June 2005, Lugano, Switzerland.**

**8- Response of 14 days-CHOP in treatment of aggressive NHL5 in relation to serum level of LDH, Be microglobultin and CA125.**

**Annals of Oncology, 9th International Conference on Management of Lymphoma, 8-11 June 2005, Lugano, Switzerland.**

**9- Study of S.VEGF and S.VCAM in patients with metastatic breast cancer and response to weekly docetaxel. Abstract Book, 16th ICACT, Feb. 1st — 4th 2005, Paris, France.**

**10- Pre-treatment cytogenetic abnormalities are predictive of induction success I adult patients with denovo acute myeloid leukemia. Abstract Book, 17th ICACT, 2005, Paris, France.**

**11- A phase Ill prospective study: comparing non-myeloablative transplantation versus conventional therapy in myelodysplastic syndromes. Abstract Book, 16th ICACT, Feb. 1st — 4th 2005, Paris, France.**

**12- Weekly docetaxel in metastatic breast cancer and correlation between serum HER-s, CEA and CA15-3. Primary therapy of early breast cancer, 8th Int. Conference, March 12-15, 2003. St. Gallen, Switzerland.**

**13- Evaluation of c-erb B2 in locally advanced and/or metastatic NSCLC and response to gemcitabine cisolatin protocol. Annals of Oncology.**

**14- Membrane and soluble APO-l as marker of apoptosis in patient with acute leukemia. Egypt. J. Nat. Cancer Inst. April, 2001**

**15- Granulocyte-Macrophage Colony Stimulating Factor GM-CSF) in acute leukemia. Book, ICACT, Feb. 4th — 7th 2002, Paris, France.**

**16- Thrombogenesis in patients with breast cancer treated with adjuvant CMF protocol. Abstract Book, ICACT, Feb. 4th — 7th 2002, Paris, France.**

**17- Prognostic value of serum IL-b soluble IL-2 receptor level in aggressive Non-Hodgkin’s Lymphoma. Abstract Book, ICACT, Feb. 4th — 7th 2002, Paris, France.**

**18- Evaluation of the patterns of bone marrow involvement in NHL by BM MRI with correlation to BM Biopsy and response to chemotherapy. Egypt, J, Nat. Cancer Inst.**

**20- Elsawy W ,Abou Taleb F ,Abdel kader M,etal.** Thymidylate Synthase Expression in Metastatic Colorectal Cancer:Correlation with the Clinical Response to Leucoverin-Modulated 5-Fluorouracil. Journal of the Egyptian Nat.Cancer Inst.2002;14(2):177-127.

**21-Prognostic significance of lung resistance protein (LRP) and multidrug resistance protein (MRP1) in patients with diffuse large B-cell NHL. Egypt. J. Nat. Cancer Inst.**

**23- Free oxygen radical activity and some antioxidants in plasma of patients with Hodgkin’s disease. The New Egyptian Journal of Medicine.**

**24- Abou Taleb F and Kamhawy S.** Bladder Preservation in Invasive Transitional Cell Cancer by TUR and CMV Chemotherapy. Journal of the Egyptian Nat.Cancer Inst.1996;8(1):59-62.

**25- Hepatic complications after autologus bone marrow transplantation for aggressive NHL5 in patients with positive Anti-HCV antibodies. Egypt. J. Nat. Cancer Inst.**

**26- Epstein-Barr virus infection and p53 overexpression in nasopharyngeal lesions. Zagazig University Medical Journal.**

**27- Dobutamine stress Echocardiography: A sensitive indicator for subclinical myocardial dysfunction in doxorubicin treated long term survivors. Zagazig Medical Association Journal.**

**28- Electrophysiological Histochemical and Histopathological studies in cytotoxic induced peripheral neuropathy. The Egyptian Rheumatologist.**

**29. Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in acute leukemia. Abst. Book, ICACT, Feb. 4th 7th 2002, Paris, France.**

**30. Thrombogenesis in patients with breast cancer treated with adjuvant CMF protocol. Abst. Book, ICACT, Feb. 4th - 7th 2002, Paris, France.**

**31. Prognostic value of serum IL- 10 and soluble IL-2 receptor level in aggressive Non-Hodgkin’s Lymphoma. Abst. Book, ICACT, Feb. 4th 7th 2 002, Paris, France.**

**32. Evaluation of p53 in relapsed and refractory aggressive NHL and response to DHAP protocol. Abstract Book, ]7th ICACT, 2006, Paris, France.**

**33. Evaluation of c-erb-B2 in locally advanced and/or metastatic NSCLC and response to gemcitabine- cisplatin protocol. Annals of Oncology 18-22 October, 2002, Nice, France.**

**34. Weekly docetaxel in metastatic breast cancer and correlation between serum HER-s, CEA and CA15.3. Primary therapy of early breast cancer, 8th int. Conference, March 12-15, 2003, St. Gallen, Switzerland.**

**35. Study of S.VEGF and S.VCAM in patients with metastatic breast cancer and response to weekly docetaxel. Abstract Book, 16th ICACT, Feb. 1st - 4th, 2005, Paris, France.**

**36. Study of S.VEGF and S.bGFR in patients with refractory NHL and response to ICE protocol. Annals of Oncology, 9th International Conference on Management of Lymphoma, 8-11 June 2005, Lugano, Switzerland.**

**37. Response of 14 days CHOP in treatment of aggressive NHLs in relation to serum level of LDH, B2 microglobulin and CA125. Annals of Oncology, 9th International Conference on Management of Lymphoma, 8-11 June 2005, Lugano, Switzerland.**

**38. A phase III prospective study: comparing non-myeloablative transplantation versus conventional therapy in myelodysplastic syndromes. Abstract Book, 16th ICACT, Feb. 1st - 4th , 2005, Paris, France.**

**39. Pre-treatment cytogenetic abnormalities are predictive of induction success I adult patients with denovo acute myeloid leukemia. Abstract.**

**40- Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus- Infected Patients Treated for Non-Hodgkin Lymphoma, Single Egyptian Center Study. J Hematol • 2013;2(1):14-21**

**41- RANDOMIZED PHASE III TRIAL OF ACVBP VERSUS CHOP- VP16 IN AGGRESSIVE NON HODGKIN LYMPHOMA (NHL). Annals of Oncology 19 (Supplement 5): v154–v156, 2008 doi:10.1093/annonc/mdn338**

**42- Gemcitabine, Dexamethasone and Cisplatin (GDP regimen) As First Salvage Treatment of Patients with Refractory or Relapsed Diffuse large B Cell Non Hodgkin Lymphoma (DLBCL). ASH 2011, Abstract 2696.**

**43- Clinical relevance of serum endoglin level in Egyptian hepatocellular carcinoma patients. Clin Lab. 2012;58(9-10):1023-8.**

# 44- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: Davies C, Pan H, Godwin J, Gray R, Arriagada R et al., ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):804.

**45- Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder. JCO vol :28, No 15\_suppl (May 20 Supplement), 2010:Abstract (4572)**

**46- Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial: An update.**

**J Clin Oncol 31, 2013 (suppl; abstr 4537).**

**47- Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial.**

**J Clin Oncol 29: 2011 (suppl 7; abstr 266).**

**48- The outcome of acute myeloid leukemia presenting with leucopenia: A retrospective study. UAE CANCER CONGRESS 2013 (POSTER PRESENTATION).**

**49- Low Dose Cytarabine With Or Without Anthracycline In The Induction Treatment Of Elderly Patients With Acute Myeloid Leukemia**

**The European Cancer Congress 2013.**

**50-** **Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial—an update. Medical Oncology, December 2013, 31:811.** [**http://dx.doi.org/10.1007/s12032-013-0811-5**](http://dx.doi.org/10.1007/s12032-013-0811-5)**.**

# 51- Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients. Journal of Cancer Research; Volume 2014 (2014), Article ID 982080, http://dx.doi.org/10.1155/2014/982080

##### 52- [**Nasr M. Ali Allahloubi**](https://www.researchgate.net/researcher/2052078145_Nasr_M_Ali_Allahloubi)**, Fouad M. Abu-Taleb,** [**Yasser A. Sallam**](https://www.researchgate.net/researcher/15817441_Yasser_A_Sallam)**,** [**Alfred E. Namour**](https://www.researchgate.net/researcher/2047419776_Alfred_E_Namour)**,** [**Mosaad M. El Gammal**](https://www.researchgate.net/researcher/2046482118_Mosaad_M_El_Gammal)**,** [**Yasser A. Hassen**](https://www.researchgate.net/researcher/2052063096_Yasser_A_Hassen). [Treatment outcomes of active multiple myeloma in two Egyptian oncology centers](https://www.researchgate.net/publication/264420582_Treatment_outcomes_of_active_multiple_myeloma_in_two_Egyptian_oncology_centers?ev=auth_pub) . Medical journal of Cairo University 06/2014; 82(2):211-216.

##### 53- Assessment of bisphosphonates use as adjuvant therapy in breast cancer. Annals of Oncology (2014) 25 (suppl\_4): iv85-iv109. 10.1093/annonc/mdu327.

**54- Rasha Haggag, Fouad Abu-Taleb .Clinicopathological features of breast cancer molecular subtypes in Egyptian women reside at Sharkia governorate. ASUCOC 2014 (poster presentation)(Abstract#5).**

**55-Thoraya Abdel Hamid, Hossam Mahmoud, Fouad Abu- Taleb, Asmaa Mahmoud, Asmaa Salama, Rasha Haggag, Hussein Khaled. Response to two treatment regimens in adult Egyptian patients with Burkitt’s lymphoma. The European Cancer Congress 2015 (ECCO) Poster presentation.** [**http://www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr**](http://www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr)**.**

**56-Rasha Haggag, Fouad Abu-Taleb, Hussein Khaled. Rituximab-Induced Hepatitis C Virus Reactivation in HCV-positive patients with diffuse large B-cell lymphoma. Cairo NCI BGO conference 2015(poster presentation).**

**57-Fouad Abu-Taleb, Rasha Haggag, Heba Abdallah, Lobna A. Abdelaziz, Hanaa Rashied . Clinicopathologic features and pattern of care of renal cell carcinoma: A retrospective study from Egypt. Cairo NCI BGO conference 2015(poster presentation).**

**58-**[**Zekri AR**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zekri%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**1,** [**Hassan ZK**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hassan%20ZK%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**,** [**Bahnassy AA**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bahnassy%20AA%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**,** [**Khaled HM**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Khaled%20HM%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**,** [**El-Rouby MN**](http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Rouby%20MN%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**,** [**Haggag RM**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Haggag%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**,** [**Abu-Taleb FM**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Abu-Taleb%20FM%5BAuthor%5D&cauthor=true&cauthor_uid=25921176)**. Differentially expressed genes in metastatic advanced Egyptian bladder cancer. Asian Pac J Cancer Prev. 2015; 16(8):3543-9.‎**

**59- Ashraf M. El-Hefnia, Nashwa M. A. Alazzazib, Fouad M. Abu Taleb, Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma. Journal of Hematology, Vol. 4, No. 1, Mar 2015.**

**60- Rasha Haggag, Fouad Abu-Taleb, Hussein Khaled.** **Rituximab-Induced Hepatitis C Virus Reactivation in HCV-positive patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 2016, 34((suppl; abstr e19039))**

**61- Shereen El Shorbagy1, Rasha Haggag, Fouad abutaleb, Hany A. Labib, Huda Ebian2,Ola A.Harb, Mona Saeed Mohammed , Hanaa A. Rashied, Khaled A Elbana, Sameh Saber** ."Prognostic Significance of VEGF and HIF 1 α in Hepatocellular Carcinoma Patients receiving sorafenib versus metformin sorafenib combination", reference #524, accepted for poster presentation at the ESMO 19th World Congress on Gastrointestinal Cancer.

**62- Hussein Khaled, Fouad Abu-Taleb, Rasha Haggag.** Hepatitis C Virus and non-Hodgkin’s lymphomas: A minireview. Journal of Advanced Research · December 2016. DOI: 10.1016/j.jare.2016.11.005.

**63-Elsawy W ,Abou Taleb F ,Abdel kader M, etal.** Prognostic Significans of Lung ResistanceProtein(LRP)and Multidrug Resistance Protein (MRP1)in Patient with Diffuse Large B-Cell Lymphoma (DLBCL) .Journal of the Egyptian Nat.Cancer Inst.2002;14(2):101-110

**64-Elsawy W , Abou Taleb F, khalifa D, et al**. Evaluation of the Patterns of Bone Marrow Involvement in Non Hodgikens Lymphoma by Bone Marrow MRI with Correlation to Bone Marrow Biobsy and Response to Chemotherapy. Journal of the Egyptian Nat.Cancer Inst.2001;13(4):267-275.

ةvement in Non HodgikenMs of Bone Marrow atic Colorectal Cancer :Coreelation 65-**Abou Taleb F,El-Far A, Elsawy W,et al.** VAD Regimen as Front Line Therapy in Multiple Myloma. Journal of the Egyptian Nat.Cancer Inst.2001;13(4):245-250.

**66-Abou Taleb F, El-Nemr D, Shawky N,et al.** Membrane and Soluble Apo-1 as a Marker of Apoptosis in Patient with Acute Leukemia. Journal of the Egyptian Nat.Cancer Inst.2002;14(1):67-74.

**67-Abou Taleb F,Farahat M ,Ibrahim I ,et al.** Hepatic Complication After Autologus Bone Marrow Transplantation for Aggressive Non-Hodgikens Lymphoma in Patients with Positive Anti-HCV Antibodies . Journal of the Egyptian Nat.Cancer Inst.1996;8(2):177-182.

**68-Abou Taleb F,Yousif M ,Khalil O, et al.** Helicobacter Pylori Infection and Hypergastrinomia As a Risk Factor for Colorectal Cancer . Journal of the Egyptian Nat.Cancer Inst.1998;10(3):303-309.

**69- ElGohary T., Abou Taleb F, Ghonaim R.** The impact of miRNA-155 expression on the treatment outcome in adult acute myeloid leukemia patients. Journal of cancer therapy, 2019, 10(03):203-214

**70-** **Thoraya Abdel Hamid, Fouad Abu Taleb, Adel Bakry, Asmaa Salama, Ayman Gaber, Shereen El Shorbagy, Mona Ramadan and Nelly Ali El Din**.

Tumor Associated Macrophages and Topoisomerase II Alpha As Prognostic Factors in Advanced Stage Hodgkin's Lymphoma. Blood 2017 130:5183.

71- **Amal Ahmed Zidan, Fouad Mohammed Abu Taleb, Alaa Abd El Moaty Omran, Ola Elsayed Abdel Latif Elnaggar. Vitamin D Receptor Gene Polymorphism as a Prognostic Marker in Acute Myeloid Leukemia Patients.** **International Journal of Pharmaceutical Research & Allied Sciences. 2018, 7(3), 81-90.**

**72- Ashraf M El Hefni, Fouad M Abu Taleb, Khaled M Hadhoud, Mahmoud A Ashour, Amal Ahmed Zidan.**  **Prognostic Assessment of P-Glycoprotein over Expression in Refractory and/or Relapsed Acute Myeloid Leukemia and Response to Cyclosporine A. Life Science Journal, 10(1), 2013.**

**73- Amal zidan, Amin Elnaggar, Fouad M Abu Taleb. Clinical relevance of dna methyltransferase 3a (dnmt3a) mutation in patients with acute myeloid leukemia .ejh. 3(17), 2018.**

**74- Fouad M Abu Taleb, Maha R Abdel-Wahid, Hala abdel-azeez Hala, abdel-azeez, Saed S Esh. Flow Cytometric Analysis of Nuclear DNA Ploidy and Proliferative Activity in Acute Lymphoblastic Leukemia. journal of the Egyptian Nat. Cancer Inst., Vol. 14, No. 4, December: 303-310, 2002.**

**75- Kohail H1, Shehata S, Mansour O, Gouda Y, Gaafar R, et al., A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes.**

**Hematol Oncol Stem Cell Ther. 2012; 5(1):42-8. doi: 10.5144/1658-3876.2012.42.**

**76- Ziad M. Alaa Ola A. Hussein, Hosneia Kh.Akl, Fouad M. Abutaleb. Detection of C-kit gene Mutation in Patients with Acute Myeloid Leukemia. Egyptian Journal of Medical Microbiology, Volume 28(1), 2019, 135-142.**

**77- Fouad M. Abutaleb , Dina El Nemr. Multidrug resistance gene-1 expression in adult acute leukemia correlation with immunophenotypingand response to chemotherapy. Zagazig medical journal. Vol(2).April.2006.**

**78- Fouad M. Abutaleb , et al., m Dina El Nemr. fluerecent in situ hybdrization detection of the 13q14.3 deletion and karyotyping analysis in B- chronic lymphativ leukemia : correlation with CD34EXPRESSION and response to therapy. Zagazig medical journal. Vol(3).April.2006**

**C . Prof. Shereen Elshorbagy**

\*Abu Taleb F, **Shereen El shorbagy**. Evaluation of response to leuprolide Acetate in Advanced Hepatocellular Carcinoma and its Relation to androgen Receptor Expression. Ann Oncol; Suppl 7: 9th world Congress on Gastrointestinal Cancer 2007: Barcelona, spain.

\*Hany A Labib, **Shereen El shorbagy**, Neveen G. Significance of telomere capture in Myelodysplastic syndrome. Medical oncology. 2014, 31910):216.

\*Maha Atfy, Hoda Ebian, **Shereen ELshorbagy**, Heba Atteia. CD200 supresses the Natural Killer Cells and Decreased its Activity in acute Myeloid Leukemia Patients. J Leukemia 3: 190; 2015.

\*Mona Hassanein, Rasha Haggag, **Shereen EL shorbagy**, Hoda F Ebian. Prognostic value of Hematogones in Patients with Acute Myeloid Leukemia In First Complete Remission. J Blood Disord Transfus 6; 319;2015.

\*Ahmed Baraka, **Shereen El shorbagy**, Hatem M Salem. Detection of Paroxysmal Hemogloinuria Clones In patients With Pancytopenia. IJAR 3, 12,866-875; 2015.

**\*Shereen El Shorbagy**, Rasha Haggag, Hoda F.Ebian. Prognostic impact of 25-hydroxyvitamin D levels in Egyptian patients with breast cancer. The Breast 24(3):S73-S74 • November 2015

**\*Shereen El shorbagy**, Rasha Haggag, Nashwa Alazizi, Tarek Abuzeid. CD19 and CD56 Antigens Expression in Acute Myeloid Leukemia Identifies Patients with Adverse Prognosis in Egypt. IJSR 5; 2016.

\*Rasha Haggag, **Shereen M. El Shorbagy**, Hoda F. Ebian, Hany A Labib. Prognostic value of Serum Cripto-1 in patients with non-small cell lung. Pan Arab Journal of Oncology/Vol. 9/No. 2/June 2016.

\*Ola A. Harb, Abdelmonem A. Hegazy, Loay M Gertallah, Rasha Haggag, **Shereen El Shorbagy**. Prognostic Assessment of Prognostic Value of Immunohistochemical expressions of the stem cell biomarker "LGR5" and the proliferation biomarker "TPX2" in colorectal carcinoma. Journal of Tumor .2016 June; 4(3): 426-434.

\*Lobna A. Abdelaziz, Ahmed Z Al Attar, **Shereen El Shorbagy**. Metronomic chemotherapy (capecitabine) in women with triple negative operable breast cancer. IJAR (2016), Volume 4, Issue 5.

\*Ola A. Harb, Amira Amin Salem, Rasha Haggag, **Shereen El Shorbagy**. Immunohistochemical Expressions of, SQSTM1 / p62, Beclin-1 and SOX4 in Infiltrating Duct Carcinoma of the Breast.

Egyptian Journal of Pathology, 2016 July. Volume36-1ssue 1:p95-103.

\*Ahmad Baraka, Mona E. Hashem**, Shereen ElShorbagy**, Mona hassanein and Salah F. Elsayed. Clinical Importance of PRAME Gene

Expression in Acute Myeloid Leukemia. J Blood Disord Transfus 2016, 7: 373.

\*Lobna A. Abdelaziz , **Shereen El Shorbagy** , Ola M Elfarargy, Ola A. Harb Abeer M Abdelbary. PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF PROGRAMMED DEATH LIGAND (PDL1) AND FOXP3 EXPRESSIONS IN TUMOR CELLS AND TUMOR MICROENVIRONMENT IN OVARIAN. CANCER PATIENTS. Int. J. Adv. Res(2017), 5(1), 1880 – 1901.

\*Lobna A. Abdelaziz, , Hoda F. Ebian, **Shereen El Shorbagy**, Rham Z.Ahmed, Ola A. Harb, ,Mariem A. Elfeky, Mohammed E.Eraki, And Loay M. Gertallah. ROLE OF S100P AS A NEW PROGNOSTIC MARKER IN WOMEN WITH METASTATIC BREAST CANCER AND ITS CORRELATION WITH BCL2 AND BAX EXPRESSION. (2017)Int. J. Adv. Res. 5(1), 1849-1868.

\*Ola A. Harb, Rasha Haggag, Maged M. Ali, **Shereen El Shorbagy**, Abeer M. Abdelbary,Lobna A. Abdelaziz, Reham A. Salim, and Khaled M. Abdel Wahab. The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma. Journal of Oncology Volume 2017.

**\*Shereen El Shorbagy**, Ola M. Elfarargy, Reham A. Salem, Amina M. Elnaggar, Ola A. Harb, Abeer M Abdelbary, Hassan R. Ashour, Loay M. Gertallah. Peripheral and tissue lymphocytes as predictors of pathological response in locally advanced rectal cancer post neoadjuvant chemoradiotherapy, Journal of Cancer Therapy, 2017, 8, 250-267

\*H. A. Atia, Tarek M. H. Ibrahim, Ashraf A. Hammam, Ashraf Metwally**, Shereen Elshorbagy**, Ahmad M. Hassaneen. Seroprevalence of Hepatitis E Virus Infection among Patients with Hematological

Malignancies in Zagazig University Hospitals, Egypt. IJSR , Volume 6 Issue 3, March 2017

\*Ahmad Baraka, **Shereen El shorbag**y, Ola M. Elfarargy, Rasha Haggag, Lobna A. Abdelaziz, Salah F. Elsayed, Khaled A. Elbana.

Significance of Apoptosis Regulators in B- cell Chronic Lymphocytic Leukemia. Journal of Cancer Therapy, 2017, 8, 360-385

\*Ola A Harb, Hanaa A Atwa, Rasha Haggag, **Shereen El Shorbagy**, Lobna A Abdelaziz, Safa A Balata, Fady M Habib and Loay M. Gertallah4The Value of HER2 neu and EphA2 expressions in Gastric Adenocarcinoma Prognosis. J Gastroint Dig Syst 2017, 7:2

\*Ahmad Baraka, Laila M. Sherief, Naglaa M. Kamal, **Shereen El shorbagy**. Detection of minimal residual disease in childhood B-acute

lymphoblastic leukemia by 4 color flowcytometry. Int J Hematol, march 2017

\*Kamel Farag , Ola M. Elfarargy, **Shereen El Shorbagy**, Reham Amin Salem, Safa A. Balata , Rasha Mohamed Abdel-latif , Ola A. Harb, Ola A. Megahed, Loay M. Gertallah. Prevalence of Androgen Receptors expression in Triple Negative Breast Cancer Patients and its Correlation with Clinicopathological Criteria: Our institutes experience. J Clin Oncol 35, 2017 (suppl; abstr e12584).

**\*Shereen El Shorbagy,** Rasha Haggag, Fouad abutaleb, Hany A. Labib, Huda Ebian, Ola A.Harb, Mona Saeed Mohammed , Hanaa A. Rashied, Khaled A Elbana. Prognostic Significance of VEGF and HIF 1 α in Hepatocellular Carcinoma Patients receiving sorafenib versus metformin

sorafenib combination. . ESMO 19 WCGIC (19 world congress on gastro intestinal cancer) Abstract Code# P-143).

# \*Thoraya Abdel Hamid, Fouad Abu Taleb, Adel Bakry, Asmaa Salama, Ayman Gaber, Shereen El Shorbagy, Mona Ramadan, Nelly Ali El Din. Tumor Associated Macrophages and Topoisomerase II Alpha As Prognostic Factors in Advanced Stage Hodgkin's Lymphoma. *Blood* (2017) 130 (Supplement 1): 5183

**\*** Ahmad Baraka, Marwa Zakaria, **Shereen EL Shorbagy**. XRCC1 polymorphism and the risk of Acute Lymphoblastic leukemia.

Published in The Egyptian Journal of Haematology in 3/2018.

\*Amal Ahmed Hazza, Mervat Mostafa Azab, Amina Elnaggar, **Shereen Elshorbagy.** Role of CD200 in adult patients with Acute myeloid leukemia. ZUMJ.2020

**\*Shereen El Shorbagy,** Fouad abutaleb, Hany A. Labib, Huda Ebian, Ola A.Harb, Mona Saeed Mohammed , Hanaa A. Rashied, Khaled A Elbana, Rasha Haggag. Prognostic Significance of VEGF and HIF- 1 α in Hepatocellular Carcinoma Patients receiving sorafenib versus metformin sorafenib combination. Journal of gastrointestinal cancer.2020

D Prof. Heba Taha

1. **Combined Ezrin overexpression and E-cadherin downregulation as predictors of invasiveness, higher incidence of metastases, progression and poor prognosis in patients with cervical cancer. (Egyptian Journal of Pathology accepted 21 December 2017, published 2018, 38:35–44).**
2. **The Value of FAK and SLUG Expression in Patients with Breast Carcinoma and Relation of Their Expression to Clinicopathological and Prognostic Parameters.** (**Journal of Clinical and Experimental Oncology 7:2, DOI: 10.4172/2324-9110.1000218).**
3. **SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell carcinoma (cc-RCC): Clinicopathological and prognostic significance. (Pathophysiology, 10.1016/j.pathophys.2018.05.004 PATPHY-946).**
4. **Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions. (Pathology & Oncology Research, November 2018, Volume 25, Issue 2, pp 611–624).**
5. **Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study. (Surgical and Experimental Pathology volume 2, Article number: 15 (2019)**
6. **The diagnostic role of Arginase1, MOC31, and CDX2 in the differentiation of hepatocellular carcinoma, cholangiocarcinoma and metastatic colonic carcinoma of the liver.(** **Middle East Journal of Cancer; October 2019; 10(4): 281-291).**
7. **Concordance between ER, PR, HER-2 neu Receptors Before and after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. (Forum of Clinical Oncology, Ref.: Ms. No. FCO-D-19-00011R1, accepted 5 November,2019).**
8. **Clinical, pathological and prognostic implications of USP22, SIRT1 and E-cadherin expression in papillary thyroid cancer (PTC) and adjacent non-neoplastic tissue. (** **Surgical and Experimental Pathology August (2019) 2:22).**
9. **The utility of diffusion‑weighted imaging in improving the sensitivity of LI‑RADS classification of small hepatic observations suspected of malignancy. (Abdominal Radiology** [**https://doi.org/10.1007/s00261-018-01887-z**](https://doi.org/10.1007/s00261-018-01887-z)**).**
10. **Prognostic Significances of NEDD-9 and FOXL-1 Expression in Intestinal Type Gastric Carcinoma: an Immunohistochemical Study.(** **Journal of Gastrointestinal Cancer** [**https://doi.org/10.1007/s12029-020-00471-3**](https://doi.org/10.1007/s12029-020-00471-3)**).**
11. **Role of HE4 and ROMA Score in Diagnosis of Ovarian Cancer in Egyptian Women. (Middle East J Cancer. 2021;12(1):p-p. doi: 10.30476/mejc.2020. 82770.1100).**
12. Amrallah A. Mohammad publications

Original research

1. Abdullah S. Al-Zahrani, Amr T. El-Kashif, Amrallah A. Mohammad, Shereef Elsamany, Samy A. Alsirafy. ***Prediction of in-hospital mortality of patients with advanced cancer using the Chuang’s Prognostic Score.*** American Journal of Hospice & Palliative Medicine, 2012 (Epub, doi: 10.1177/1049909112467362).
2. Samy A. Alsirafy, Amrallah A. Mohammad, Abdullah S. Al-Zahrani, Amr T. ElKashif, Ahmad A. Raheem. ***The Relation Between the Timing of Palliative Care and the Frequency and Timing of Do-Not-Resuscitate Orders Among Cancer Deaths in a Tertiary Care Hospital.*** AM J HOSP PALLIAT CARE published online 26 March 2014 (DOI: 10.1177/1049909114529014.
3. Amrallah A. Mohammed, Abdullah S. Al-Zahrani , Mohamed A. Sherisher, Ahmad A. Alnagar, Ayman EL-Shentenawy , Amr T. El-Kashif. ***The pattern of infection and antibiotics use in terminal cancer patients. Journal of the Egyptian*** National Cancer Institute. Published online 13 June 2014.
4. Amrallah A. Mohammed, Abdullah S. Al-Zahrani, Amr T. El-Kashif, MBBCh. ***Clinicopathological Features of Gastric Cancer; Single Center Experience.*** Pan Arab Journal of Oncology | vol 7; issue 1 | March 2014.
5. Abeer A. Bahnassy, Abdel-Rahman N. Zekri, Samah A. Loutfy, Waleed S. Mohamed, Amrallah A. Mohammed, Salem E. Salem, Marwa M. Sheta, Ashraf Omar, Heba Al-Zawahry.***The role of cyclins and cyclin dependent kinases in development and progression of hepatitis C virus-genotype 4-associated hepatitis and hepatocellular carcinoma***. Experimental & Molecular Pathology, 91(2):64352; 2011.
6. Amrallah A. Mohammed, Abdullah S. Al-Zahrani, Amr T. El-Kashif, Hafez Ghanem and Amer El-Kashif. ***Pattern of venous thrombosis in cancer patients: frequency and survival effect: single center experience.*** Indian Journal of Hematology and Blood Transfusion ISSN 0971-4502 Indian J Hematol Blood Transfus DOI 10.1007/s12288-014-0496-8.
7. Samy A. Alsirafy , Ahmad A. Raheem , Abdullah S. Al-Zahrani, Amrallah A. Mohammed, Mohamed A. Sherisher , Amr T. El-Kashif , Hafez M. Ghanem. ***Emergency department visits at the end-of-life of terminally-ill***. American Journal of Hospice & Palliative Medicine. DOI: 10.1177/1049909115581819.
8. Amrallah A. Mohammed, Abdullah S. Al-Zahrani , Hafez M. Ghanem , Mian U. Farooq, Amr M. El Saify , Hani M. EL-Khatib. ***End-of-life palliative chemotherapy: Where do we stand?*** Journal of the Egyptian National Cancer Institute (2015) 27, 35–39
9. Amrallah A. Mohammed,Hani EL-Tanni , Hafez M. Ghanem ,Mian U. Farooq ,

Amr M. El Saify , Abdullah S. Al-Zahrani ,Ayman EL-Shentenawy, Hani M. ELKhatib. ***Impact of body mass index on clinico-pathological parameters and*** outcome in patients with metastaticprostate cancer Journal of the Egyptian National Cancer

Institute (2015) 27, 155–159

1. A Rasmy, W Abozeed, S Elsamany, M El Baiomy5, A Nashwa, Amrallah A. Mohammed, E Hasaan, A Alzahrani, M Faris, K Alsaleh, A AlFaraj ***Correlation of***

***Preoperative Ki67 and CA15.3 Levels with Outcome in Early Breast Cancer - a Multi Institutional Study*** Asian Pac J Cancer Prev, 17 (7), 3595-3600

1. Shereef Elsamany, Soha Elmorsy, Abdullah Alzahrani1, Ayman Rasmy, Waleed N Abozeed, Amrallah A. Mohammed,, Mohamed A Sherishe, Mohammed M Abbas1, Miral Mashhou.***Predictive Value of IHC4 Score for Pathological***

***Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast*** Cancer Asian Pac J Cancer Prev, 16 (17), 7975-7979

1. Gamal M Elnemr, Ahmed H El-Rashidy, Ahmed H Osman, Lotfi F Issa, Osama A Abbas8, Abdullah S Al-Zahrani10, Sheriff M El-Seman10,11, Amrallah A Mohammed12, Abdelghani A Hassan13,Response of ***Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.*** Asian Pac J Cancer Prev, 17 (2), 807-813.
2. A. Mirza1, Mohammed A. Al-Sakkaf2, Amrallah A. Mohammed3, Mian U. Farooq4, Ziad A. Al-Ahmadi5, Mohammed A. ***Patterns of Inpatient Admissions during Hajj: Clinical conditions, length of stay and patient outcomes at an advanced care centre in Makkah, Saudi Arabia*** Pak J Med Sci July - August 2018.
3. Engy M Aboelnaga1, Rasha Hamdy Hamed1, Amir M zeid2 and Amrallah A Mohammed3 ***Neoadjuvant Platinum and Gemcitabine Regimens Precede Definitive Radiotherapy in Locally Advanced Bladder Cancer***. Cancer Science & Research. 5(2):8.
4. Anter AH, Hamed RH, Mohammed AA. ***Efficacy and Safety of First-Line Pazopanib in Patients with Metastatic Renal Cell Carcinoma: Real-Life Multi Institutional Experience.*** Clin Oncol. 2019; 4: 1605.
5. Mohammed AA, Al-Zahrani O, Salem RA, Elsayed FM. ***Aggressive care at the end of life; Where are we? Indian J Palliat Care 2019; 25:539-43.***
6. Amrallah A Mohammed1\*, Hayam E Rashed2, Aziza E Abdelrahman2, Ahmed A Obaya3, Mostafa Toam3, Hanim M Abdel Nour4, Mohamed I Abdelhamid5, Fifi Mostafa Elsayed6. ***C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.*** Asian Pacific Journal of Cancer Prevention, Vol 2.
7. Amrallah A Mohammed1,2\*, Fifi Mostafa Elsayed3, Mohammed Algazar4, Hayam E Rashed5, Abeer Hussien Anter. ***Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.*** Asian Pacific Journal of Cancer Prevention, Vol 21.

# Review articles

1. Amrallah A. Mohammed & Ayman ELShentenawy. ***Advanced thyroid cancers: new era of treatment***. Med Oncol (2014) 31:49. DOI 10.1007/s12032-014-0049-x
2. Amrallah A. Mohammed. ***Biomarkers in prostate cancer: new era and prospective.*** Med Oncol (2014) 31:140 DOI 10.1007/s12032-014-0140-3.
3. Amrallah A. Mohammed and Hahez Ghanem. ***Scope of management of nausea and vomiting in palliative care: review.*** Arab Journal of Oncology | vol 7; issue 1 | March 2014.
4. Amrallah A. Mohammmad, Abdullah Alzahran and Hani El-Tanni. ***Denosumab in the treatment of bone metastasis from solid tumors.*** Pan Arab Journal of Oncology | vol 6; issue 4 | December 2013.
5. Amrallah A. Mohammed, Abdullah S. Al-Zahrani and Hafez Ghanem. ***Gastro intestinal obstruction in palliative care, forum of clinical oncology.*** HeSMO • 6(1) • 2015 • 1–5 DOI: 10.1515/fco-2015-0001
6. Amrallah A. Mohammed, Abdullah S. Al-Zahrani and Hafez Ghanem.

***Scope of management of emergency in palliative care, in Forum Of Clinical oncology.***

1. Amrallah A. Mohammed, Ayman M. EL-Shentenawy, Mohamed A. Sherisher, and Hani M.EL-Khatib. Target therapy in metastatic ***pheochromocytoma: current perspectives and controversies. In press; oncology review.***
2. Amrallah A. Mohammed1,2,5Hani EL-Tanni. ***Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed.*** Indian J Hematol Blood Transfus Received: 20 May 2015 / Accepted: 2 February 2016
3. Amrallah A. Mohammed,1,2 Hani EL-Tanni,2 Hani M. EL-Khatib,2 Ahmad A. Mirza,3Abdulrahim A. Mirza,4 Turki H. Alturaifi4 Urinary bladder cancer: ***biomarkers and target therapy, new era for more attention*** Oncology Reviews 2016; 10:320]
4. Amrallah A. Mohammed et al.Genomic aberrations in non- small cell lung cancer and

their impact on treatment outcome Journal of Cancer Research and Therapeutics | Published by Wolters Kluwer - Medknow

1. Amrallah A. Mohammad. Advanced pancreatic cancer: The standard of care and new opportunities [Oncology Reviews 2018; 12:370]
2. Amrallah A. Mohammad. Myelodysplastic syndrome from theoretical review to clinical application view. [Oncology Reviews 2018; 12:397]
3. Amrallah A. Mohammed,1,2Hanaa Rashied,3Fifi Mostafa Elsayed4 CDK4/6 inhibitors in advanced breast cancer, what is beyond? [Oncology Reviews 2019; 13:416].

# Case reports

1. Amrallah A. Mohammmad, Abdullah Alzahrani, Ahmad Abdel Raheem, Amr El-Kashif1. ***Metastatic Triple-Negative Breast Cancer; Unusual Presentation***. Pan Arab Journal of Oncology | vol 6; issue 4 | December 2013.
2. Amrallah A. Mohammmad, Abdullah Alzahrani,Ahmad Abdel Raheem, and Hani ElTanni. ***Bilateral Breast Cancer- A case Report***. Pan Arab Journal of Oncology | vol 6; issue 3 | September 2013.
3. Abdullah Alzahrani, Amr El-Kashif, Hani EL-Khatib,Amrallah A.Mohammmad, Ahmad Abdel Raheem. ***Metastatic Gallbladder Cancer with Complete Response after Cisplatinum/Gemcitabine Chemotherapy***; Case Report. Pan Arab Journal of Oncology | vol 5; issue 2 | June 2012.
4. Amrallah A. Mohammmad, Abdullah Alzahrani1, Ayman El-Shentenawy, Esmail AlEzzi.***Leptomeningeal metastasis from gastroesophageal carcinoma***. FORUM of CLINICAL ONCOLOGY.
5. Amrallah A.Mohammmad, Abdullah Alzahrani Hani EL-Khatib. ***Double primary cancers registered in tertiary care hospital; Review of cases***. JOURNAL OF CASE REPORTS 2014;4(1):72-76.
6. Amrallah A. Mohammed, Abdullah S. Al-Zahrani and Amr T. El-Kashif. ***Pseudopapillary carcinoma of pancreas.*** Case report; in American journal of cancer case report.
7. Amrallah A. Mohammed, Abdullah S. Al-Zahrani and Hani Khatib. ***Triple primary carcinomas: prostatic adenocarcinoma,*** American Journal of Cancer Case Reports http://ivyunion.org/index.php/ajccr Vol 3 Article ID 20140600, 5 pages.

# Abstracts and posters

1. Abdullah S. Al-Zahrani, Amr T. El-Kashif, Amrallah A. Mohammad, Shereef Elsamany. Timing of adjuvant chemotherapy in colon cancer: impact on survival parameters. Abstract and poster in esmo 2013; ABSTRACT - ECC2013 - POSTER SESSION.
2. Amrallah A. Mohammed, Abdullah S. Al-Zahrani , Mohamed A. Sherisher, Ahmad A. Alnagar, Ayman EL-Shentenawy , Amr T. El-Kashif. The pattern of infection and antibiotics use in terminal cancer patients.
3. Abstract and poster in 6th Asian Oncology Summit and 10th Annual Conference of the Organisation for Oncology and Translational Research; April 11-13, 2014, Shangri La Hotel, Kuala Lumpur, Malaysia. [Abstract Reference

Number: AOS2014\_0023 ]

1. Abstract and poster in Hospice Palliative Care Ontario Annual Conference April 27 - 29, 2014.

III. Amrallah A. Mohammed, Abdullah S. Al-Zahrani, Amr T. El-Kashif, MBBCh. Clinicopathological Features of Gastric Cancer; Single Center Experience.

Abstract and poster in 6th Asian Oncology Summit and 10th Annual Conference of

the Organisation for Oncology and Translational Research; April 11-13, 2014, Shangri La Hotel, Kuala Lumpur, Malaysia. [Abstract Reference Number: AOS2014\_0037].

1. **Prof. Ahmad Elnaggar publications** 
   1. Pre- treatment cytogenetic abnormalities are predictive of induction success in adult patients with de novo acute myeloid leukemia ,Poster Abstract in the ICACT which was held in France from 30 Jan.-2 Feb 2006.
   2. Metasatic Gallbladder Cancer with Complete Response after Cisplatinum / Gemcitabine Chemotherapy: Case Report. Pan Arab Journal of Oncology / vol 5 :issue 2/june 2012.
   3. Low Dose Cytarabine With Or Without Anthracycline In The Induction Treatment Of Elderly Patients With Acute Myeloid Leukemia. European Cancer Congress 2013. Abstract No 3646.
   4. Clinico-pathological pattern of colorectal cancer in young patients, western Saudi Arabia experience. Asia Pacific Gastroenterology Cancer Summit 2013. Abstract No 121
   5. The pattern of infection and antibiotics use in terminal cancer patients, Journal of the Egyptian National Cancer Institute(2014)26,147–152.
   6. Clinico-Pathological Patterns and Survival Outcome of Colorectal Cancer in Young Patients: Western Saudi Arabia Experience, Asian Pac J Cancer Prev,(2014) 15 (13), 5239-5243.
   7. Assessment of bisphosphonates use as adjuvant therapy in breast cancer, Annals of Oncology (2014) 25 (suppl\_4): iv85-iv109.
   8. The Relation Between the Timing of Palliative Care and the Frequency and Timing of Do-Not-Resuscitate Orders Among Cancer Deaths in a Tertiary Care Hospital, American Journal of Hospice &Palliative Medicine® 2015,Vol.32(5)544-548.
   9. Emergency Department Visits at the End of Life of Patients With Terminal Cancer: Pattern, Causes, and Avoidability , ajhpm.sagepub.com.
   10. The fear of using tramadol for pain control (tramadolophobia) among Egyptian patients with cancer,Journal of Opioid Management 11:6 n November/December 2015,463-469.
   11. Significance of PAX (CDX2) gene expression in adult acute Myeloid leukemia. International Journal of Advanced Research (2015), Volume 3, Issue 10 , 1585 – 1592.
   12. Role of reduced dose CHOP with Rituximab plus involved field radiotherapy in treatment of early stage diffuse large B –cell lymphoma in elderly patients. Journal of American Science 2016;12(6),116-123.
   13. Can Resection Of Liver Metastasis Improve Survival After Resectability Conversion Chemotherapy In Patients With Metastatic Colo-Rectal Cancer? International Journal of Advanced Research (2016), Volume 4, Issue 4, 489-497.
   14. The role of oncogenic infectious agents in causing liver, stomach, urinary bladder , head and neck and cervical cancers. Human Virology and Retrovirology 2016;3(2):00087.
   15. Methicillin Resistant Staphylococcus aureus Antibiotic Profile and Genotypes in Critically Ill Neurosurgery and Medical Oncology Patients. EC Microbiology 3.2 (2016): 412-423.
   16. Significance of neuropilin-1 mRNA expression in chronic myeloid leukemia. Egyptian Journal of Haematology, Vol. 41 No. 4, October-December 2016,187-193.
   17. Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. HEMATOLOGY, 2017 VOL. 22, NO. 7, 392–397 <http://dx.doi.org/10.1080/10245332.2017.1292204>
   18. Evidence-based assessment of the burden of infection related solid tumors. Annals of Oncology 27(Supplement 2):ii86–ii101,2016 doi:10.1093/annonc/mdw201.48
   19. Multi-focal superficial basal cell carcinoma of nipple and areola of 60 yearsfemale: A case report and a mini review Human Pathology: Case Reports 14 (2018) 52–56
   20. Serum IgE and Allergy Related Genotypes of IL-4R α and IL-13 Genes: Association with Glioma Susceptibility and Glioblastoma Prognosis. Source: NCBI PubMed ( ID PMID:30242995 ). Egypt J Immunol,2018/1;25(1):19-33.
   21. Study of CD160 expression in B-chronic Lymphocytic Leukemia. DOI: 10.21608/zumj.2020.27530.1802
   22. Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation. clinical-lymphoma-myeloma-leukemia,Volume 20, ISSUE 7, P459-467, July 01, 2020
   23. ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy. Cancer Biomark 2020 ;27(2):251-264
   24. Prognostic impact of immunohistochemical expression of claudin-4 and epithelial mesenchymal-related markers (Snail-1) in breast invasive duct carcinoma. <https://doi.org/10.1016/j.senol.2020.10.003>
   25. Prognostic Value of Interleukin-17 A Gene Polymorphism and Serum IL-17 Levels in Adult Acute Myeloid Leukaemia Patients .The Egyptian Journal of Hospital Medicine (October 2020) Vol. 81 (2), Page 1352-1358
   26. Study of Wilms’ tumor 1 gene expression in patients with acute myeloid leukemia. Egyptian Journal of Haematology 2019 44:195–203
   27. Brain and Acute Leukemia, Cytoplasmic Gene Overexpression as a Prognostic Factor in Egyptian De novo Adult Acute Myeloid Leukemia Patients.J Med Paediatr Oncol 2020;41:859-68. DOI: 10.4103/ijmpo.ijmpo\_215\_20
   28. Tailoring chemotherapy according to KRAS mutation type in metastatic colorectal cancer. Sapporo Medical Journal,Volume 55, Issue 02, February, 2021

Dr . Asmaa A. Mahmoud publications

Ahmed A. Alnagar, Asmaa A. Mahmoud,1 Mosaad M. EL Gammal, Naera Hamdy, Mohamed A. Samra. Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation.

Clinical Lymphoma, Myeloma & Leukemia, Vol. 20, No. 7, 459-67

Dr. Ahmad B Waley

Hussein M Khaled, Thoraya M Abdelhamid, Fouad M Abu-Taleb

, Niveen M El-Hifnawi& Ahmad B Waley. Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen. Future Science OAVol. 5, No. 9